Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

Annals of Oncology

Volumn 24, Issue 2, 2013, Pages 309-314

  Vilmar, A C ^a   Santoni Rugiu, E ^b   Sorensen, J B ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Gemcitabine; NSCLC; Predictive biomarkers; RRM1; Vinorelbine

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; RADIATION-SENSITIZING AGENTS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VINBLASTINE; YOUNG ADULT;

EID: 84873800406     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds335     Document Type: Article

References (31)

1. Maemondo M, Inoue A, Kobayashi K et al. A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the firstline treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study. Eur J Cancer Suppl 2009; 7(3), 6. 9-10-0009.
2. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
3. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
4. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
5. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
6. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
7. Poole AM, Logan DT, Sjoberg BM. The evolution of the ribonucleotide reductases: much ado about oxygen. J Mol Evol 2002; 55: 180-196.
8. Gazdar AF. DNA repair and survival in lung cancer-the two faces of Janus. N Engl J Med 2007; 356: 771-773.
9. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006; 24: 4731-4737.
10. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-1825.
11. Simon G, Sharma A, Li X et al. Feasibility and efficacy of molecular analysisdirected individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007; 25: 2741-2746.
12. Lee JJ, Maeng CH, Baek SK et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer 2010; 70: 205-210.
13. Wang X, Zhao J, Yang L et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-smallcell lung cancer. Med Oncol 2010; 27(2): 484-490.
14. Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-9556.
15. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14: 7167-7172.
16. Vilmar AC, Santoni-Rugiu E, Sorensen JB. Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 2011; 17: 5205-5214.
17. Seve P, Mackey J, Isaac S et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4: 2001-2007.
18. Rabbani-Chadegani A, Chamani E, Hajihassan Z. The effect of vinca alkaloid anticancer drug, vinorelbine, on chromatin and histone proteins in solution. Eur J Pharmacol 2009; 613: 34-38.
19. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
20. Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010; 21(9): 1817-1824.
21. Azuma K, Komohara Y, Sasada T et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007; 98: 1336-1343.
22. Holm B, Mellemgaard A, Skov T et al. Different impact of excision repair crosscomplementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol 2009; 27: 4254-4259.
23. Reynolds C, Obasaju C, Schell MJ et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009; 27: 5808-5815.
24. Wang X, Zhao J, Yang L et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-smallcell lung cancer. Med Oncol 2010; 27: 484-490.
25. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10: 1318-1325.
26. Gao Z, Han B, Shen J et al. Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 2011; 14: 340-344.
27. Liang W, Hu C, Gu Q et al. Effects of expression of ERCC1, RRM1 on survival trend of lung cancer with cisplatin combine gemcitabine chemotherapy after surgical resection.. Zhongguo Fei Ai Za Zhi 2009; 12: 403-407.
28. Lee HW, Choi YW, Han JH et al. Expression of excision repair crosscomplementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 2009; 65: 377-382.
29. Ramos-Vara JA. Technical aspects of immunohistochemistry. Vet Pathol 2005; 42: 405-426.
30. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-808.
31. Gomez-Roca C, Raynaud CM, Penault-Llorca F et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 2009; 4(10): 1212-1220.